Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
A study to review Wilson disease patients who have previously been prescribed d-
 Penicillamine but were changed to trientine as treatment for their disease, and to follow
 them for a further 12 months.
A retrospective study to review Wilson disease patients who have previously been prescribed
 d- Penicillamine but were changed to trientine as treatment for their disease, and to follow
 them prospectively for a further 12 months.
Inclusion Criteria:

 -  Patients aged 1 year to 90 years of age.

 -  Physician established diagnosis of Wilson disease based on a Ferenci score > 3.

 -  Documented treatment with d-Penicillamine, withdrawal of treatment with d-
 Penicillamine, followed by treatment with trientine for at least 6 months at date of
 informed consent.

 -  Able/willing to provide written informed consent.

 -  For enrolment in the prospective part, enrolment in the retrospective part of the
 study is required.

 Exclusion Criteria:

 -  Incomplete history of medication use for trientine from initial diagnosis to latest
 follow up.

 -  Unavailable outcome data for hepatic and neurological course of disease at assessment
 time points.

 -  Patients with acute liver failure and fulminant hepatic disease with fatal outcome.

 -  Hypersensitivity to trientine and severe anaemia.